

## 2025 CoxHealth South Antibigram: Gram Positive

	<i>Staphylococcus aureus</i>	<i>Staphylococcus aureus (MSSA)</i>	<i>Staphylococcus aureus (MRSA)</i>
No. of isolates	<b>445</b>	<b>271</b>	<b>174</b>
Penicillin	<b>21</b>	<b>35</b>	
Oxacillin	<b>60</b>	<b>100</b>	
Cefazolin	<b>60</b>	<b>100</b>	
Clindamycin	<b>73</b>	<b>78</b>	<b>64</b>
Erythromycin	<b>44</b>	<b>65</b>	<b>16</b>
Tetracycline	<b>85</b>	<b>91</b>	<b>76</b>
Trim/Sulfa	<b>98</b>	<b>99</b>	<b>96</b>
Linezolid	<b>100</b>	<b>100</b>	<b>100</b>
Vancomycin	<b>100</b>	<b>100</b>	<b>100</b>
Daptomycin	<b>100</b>	<b>100</b>	<b>100</b>

For purposes of antibiogram calculations, intermediate results are tabulated as resistant. Numbers shown are percentage of isolates that are susceptible.


85-100% of isolates susceptible

60-84% of isolates susceptible

0-59% of isolates susceptible

Not routinely tested or insufficient data

Intrinsically Resistant



## 2025 CoxHealth South Antibigram: Gram Negative

	<i>Escherichia coli</i>	<i>Enterobacter cloacae</i>	<i>Serratia marcescens</i>	<i>Klebsiella pneumoniae</i>	<i>Klebsiella oxytoca</i>	<i>Klebsiella aerogenes</i>	<i>Proteus mirabilis</i>	<i>Pseudomonas aeruginosa</i>
No. of Isolates	1,366	66	33	202	58	32	130	155
Ampicillin	60	#	#	#	#	#	72	#
Amoxicillin/Clavulanate	90			91	97		90	#
Ampicillin/Sulbactam	67			83	76		80	#
Piperacillin/Tazobactam	98	&	85	94	98	&	96	94
Cefazolin	78			84	22		60	#
Cefazolin <sup>(U)</sup>	90			88			85	#
Ceftriaxone	93	&	85	89	98	&	94	#
Ceftazidime	95	&	82	91	98	&	97	91
Cefepime	94	94	94	89	98	100	94	92
Ertapenem	100	97	94	99	98	100	97	
Meropenem	100	100	94	99	98	100	97	95
Imipenem-Cil	100	94		99	98			85
Aztreonam	94	&	85	89	98	&	95	85
Amikacin	99	100	100	99	98	100	95	96
Gentamicin	92	97	100	95	97	100	82	
Tobramycin	88	97	58	91	98	100	75	94 <sup>#</sup>
Ciprofloxacin	84	91	94	86	97	97	67	74
Levofloxacin	87	94	94	91	98	97	69	72
Tetracycline	82	91		78	95	94	#	
Trim/Sulfa	80	89	100	84	98	100	72	#

For purposes of antibiogram calculations, intermediate results are tabulated as resistant. Numbers shown are percentage of isolates that are sensitive.

<sup>(U)</sup> These susceptibilities are only based on urinary breakpoints

<sup>#</sup> Tobramycin does not predict susceptibility to gentamicin, CLSI has removed gentamicin as an effective agent for treatment of *Pseudomonas aeruginosa* infections.

85-100% of isolates susceptible

60-84% of isolates susceptible

0-59% of isolates susceptible



Not routinely tested or insufficient data

Intrinsically Resistant

Inducibly Resistant

